Sarepta Stock (SRPT) Primed for 200% Surge—Even as Wall Street Gets Cold Feet
Wall Street’s skepticism is growing—but Sarepta Therapeutics (SRPT) might be sitting on a powder keg of upside.
Here’s why the biotech play could defy the doubters.
The bull case: 200% or bust
Analysts whispering about triple-digit gains aren’t just blowing smoke. SRPT’s pipeline has catalysts that could send institutional FOMO into overdrive.
The bear trap: Shorts betting against hope
Sure, the FDA’s approval process is a regulatory minefield—but since when did that stop a biotech moonshot? (Cue cynical jab: Remember when Wall Street said Bitcoin would never hit $10K?)
The bottom line
This isn’t a stock for the faint-hearted. But for traders who live in the explosive intersection of data and speculation? Buckle up.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
For context, Sarepta is focused on developing genetic medicines to treat rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD).
What’s Happening with SRPT Stock?
SRPT began the week on a sharp downturn, with shares plunging as much as 46% on Monday following confirmation of a second patient death tied to its DMD gene therapy, Elevidys. In response, Sarepta and its global partner Roche (RHHBY) have suspended both commercial and clinical use of the treatment in non-ambulatory patients, pending a comprehensive safety review.
The company first disclosed a patient death linked to Elevidys in March. Both non-ambulatory patients experienced acute liver failure following treatment. Year-to-date, SRPT stock declined by over 80%.
The tragic development triggered a wave of analyst downgrades and raised serious concerns about the future of Elevidys, a key driver of Sarepta’s long-term growth narrative. Nonetheless, some investors see the pullback as a strategic entry point rather than a red flag, given its first-mover advantage in Duchenne muscular dystrophy treatment.
Analysts Turn Cautious on SRPT Stock
Notably, H.C. Wainwright analyst Mitchell Kapoor downgraded SRPT from Neutral to Sell earlier this week, slashing the price target from $40 to $10. Kapoor cited heightened risks associated with Elevidys and warned that patients and physicians may avoid the therapy unless long-term data confirms a very low risk of treatment-related death.
Meanwhile, Piper Sandler and Morgan Stanley also downgraded SRPT from Buy to Hold, cutting their price targets. Moreover, Needham trimmed its target from $125 to $50, while UBS sharply lowered its estimate from $188 to $85, reflecting broader caution across Wall Street.
Needham analyst Gil Blum cut his revenue forecast for Elevidys to $969 million from $1.4 billion, excluding all non-ambulatory patients. Sarepta has also temporarily suspended its revenue guidance.
What is SRPT’s Stock Price Forecast?
According to TipRanks, Wall Street has a Moderate Buy consensus rating on SRPT stock, based on 15 Buys, nine Holds, and one Sell assigned in the last three months. The average Sarepta Therapeutics stock price target of $64.50 implies a 199.17% upside potential.
